查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1393489

全球藥物遺傳學測試市場 - 產業趨勢與預測（~2030 年）

Global Pharmacogenetic Testing Market - Industry Trends and Forecast to 2030
出版日期: | 出版商: Data Bridge Market Research | 英文 356 Pages | 商品交期: 請詢問到貨日

價格

全球藥物基因檢測市場規模將從 2022 年的 59.6 億美元增至 2030 年的 114.424 億美元，預計在 2023-2030 年預測期內複合年增長率為 8.7%。

本報告針對全球藥物遺傳學檢測市場進行研究分析，提供產業趨勢與預測、驅動與約束因素、公司趨勢等資訊。

目錄

第一章簡介

第二章市場區隔

第 3 章執行摘要

第 4 章重要考量

  • PESTEL 分析
  • 波特五力分析
  • 產業考量與策略分析

第五章市場概論

  • 促進因素
    • 越來越多採用個人化醫療
    • 基因體技術的進步
    • 慢性和複雜疾病的增加
    • 藥物基因學測試在藥物發現和開發中的作用
  • 抑制因素
    • 依賴醫學和基因組專家來解釋結果
    • 與藥物基因學測試相關的道德和隱私問題
  • 機會
    • 與電子健康記錄 (EHR) 集成
    • 將人工智慧和機器學習融入醫療保健領域
  • 作業
    • 藥物基因學臨床實施面臨的挑戰
    • 與藥物基因學測試結果相關的複雜性

第 6 章全球藥物基因測試市場：依類型

  • 摘要
  • 全基因組定序
    • 次世代定序 (NGS)
    • 桑格定序
  • 全外顯子定序
    • 次世代定序 (NGS)
    • 桑格定序
  • 基於陣列的檢查
    • 玻片陣列
    • 原位合成陣列
    • 自組數組
  • 單基因檢測
    • 次世代定序 (NGS)
    • 桑格定序

第 7 章全球藥物基因學測試市場：依基因型區分

  • 摘要
  • CYP2C19
  • CYP2D6
  • CYP2C9、VKORC1
  • CYP1A2
  • HLA-B 1502
  • HLA-B 5701
  • CYP2D
  • OPRM1
  • ONCOTYPE DX、MammaPrint
  • DRD3
  • D4D4
  • SLC6A4
  • HTR2A/C
  • TMPT
  • 其他

第 8 章全球藥物基因學測試市場：依藥物類型

  • 摘要
  • 處方藥
  • 營養補充品
  • 消遣性毒品
  • 草藥補充劑
  • 維生素
  • 非處方藥

第 9 章全球藥物基因測試市場：依樣本

  • 摘要
  • 血
  • 唾液

第 10 章全球藥物基因學測試市場：依治療領域劃分

  • 摘要
  • 心
  • 胃腸病學
  • 麻醉
  • 基因體學
  • 內分泌
  • 免疫/過敏
  • 皮膚
  • 婦科
  • 腫瘤
  • 緊張
  • 其他

第 11 章全球藥物基因學測試市場：按應用劃分

  • 摘要
  • 臨床治療
  • 藥物發現與開發
  • 藥物管制

第 12 章全球藥物基因測試市場：按最終用戶劃分

  • 摘要
  • 醫療保健提供者
  • 製藥公司、生技公司
  • 研究中心、學術機構
  • 其他

第 13 章全球藥物基因測試市場：依分銷管道劃分

  • 摘要
  • 醫院藥房
  • 零售藥局
  • 郵購藥房
  • D2C 服務

第 14 章全球藥物基因學測試市場：按地區

  • 摘要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東/非洲

第 15 章全球藥物基因測試市場：公司狀況

  • 公司股票分析：全球
  • 公司股票分析：北美
  • 公司股票分析：歐洲
  • 公司股票分析：亞太地區

第16章SWOT分析

第十七章公司簡介

  • THERMO FISHER SCIENTIFIC INC.
  • ILLUMINA, INC.
  • QIAGEN
  • SONIC HEALTHCARE
  • BGI
  • 23ANDME, INC
  • DYNAMIC DNA LABORATORIES
  • EUROFINS SCIENTIFIC (2022)
  • GENEWIX (A SUBSIDIARY OF AZENTA LIFE SCIENCE)
  • LUMINEX CORPORATION (A SUBSIDIARY OF DIASORIN)
  • MD LABS
  • MYRIAD GENETICS, INC.
  • ONEOME
  • PACBIO
  • PERKINELMER INC.
  • PGXT

第 18 章調查

第十九章相關報告

The global pharmacogenetic testing market is expected to reach USD 11,442.40 million by 2030 from USD 5,960.00 million in 2022, growing at a CAGR of 8.7% during the forecast period of 2023 to 2030.

Market Segmentation

Global Pharmacogenetic Testing Market, By Type (Whole Genome Sequencing, Whole Exome Sequencing, Array-Based Tests, and Single Gene Tests), Gene Type (CYP2C19, CYP2D6, CYP2C9 AND VKORC1, CYP1A2, HLA-B*1502, HLA-B*5701, CYP2D, OPRM1, ONCOTYPE DX AND MAMMAPRINT, DRD3, D4D4, SLC6A4, HTR2A/C, TMPT, and Others), Drug Type (Prescription Drugs, Nutraceuticals, Recreational Drugs, Herbal Supplements, Vitamins, and Over-the-Counter Medications), Sample (Blood and Saliva), Therapeutic Area (Cardiology, Gastroenterology, Anesthesiology, Genomics, Endocrinology, Immunology & Hypersensitivity, Dermatology, Gynecology, Oncology, Neurology, and Others), Application (Clinical Practice, Drug Development, and Drug Regulation), End User (Healthcare Providers, Pharmaceutical & Biotechnology Companies, Research Centres and Academic Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacies, Mail-Order Pharmacies, and Direct-to-Customer Services), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, rest of Middle East and Africa) - Industry Trends and Forecast to 2030.

Overview of Global Pharmacogenetic Testing Market Dynamics

  • Driver
  • Rapid technological advancement and miniaturization
  • Restrain
  • Environment and health concerns
  • Opportunity
  • Rising research and development and innovative technologies

Market Players

Some of the major market players operating in the global pharmacogenetic testing market are:

  • Thermo Fisher Scientific
  • Illumina, Inc
  • QIAGEN
  • Sonic Healthcare
  • BGI
  • PerkinElmer Genomics
  • Eurofins Scientific
  • 23andMe Holding Co.
  • GENEWIZ (A subsidiary of Azenta Life Sciences)
  • Luminex Corporation. (A subsidiary of DiaSorin S.p.A.)
  • PacBio.
  • Assurex Health, Inc. (A subsidiary of Myriad Genetics)
  • MD Labs
  • OneOme, LLC
  • Dynamic DNA Laboratories
  • PGXT

TABLE OF CONTENTS

1 INTRODUCTION 41

  • 1.1 OBJECTIVES OF THE STUDY 41
  • 1.2 MARKET DEFINITION 41
  • 1.3 OVERVIEW OF GLOBAL PHARMACOGENETIC TESTING MARKET 41
  • 1.4 CURRENCY AND PRICING 43
  • 1.5 LIMITATIONS 43
  • 1.6 MARKETS COVERED 44

2 MARKET SEGMENTATION 47

  • 2.1 MARKETS COVERED 47
  • 2.2 GEOGRAPHICAL SCOPE 48
  • 2.3 YEARS CONSIDERED FOR THE STUDY 49
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 50
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 53
  • 2.6 DBMR MARKET POSITION GRID 54
  • 2.7 MULTIVARIATE MODELLING 55
  • 2.8 TYPE LIFELINE CURVE 56
  • 2.9 MARKET END USER COVERAGE GRID 57
  • 2.10 SECONDARY SOURCES 58
  • 2.11 ASSUMPTIONS 58

3 EXECUTIVE SUMMARY 59

4 PREMIUM INSIGHTS 62

  • 4.1 PESTEL ANALYSIS 63
  • 4.2 PORTER'SFIVE FORCES 64
  • 4.3 INDUSTRY INSIGHTS AND STRATEGIC ANALYSIS 65

5 MARKET OVERVIEW 66

  • 5.1 DRIVERS 68
    • 5.1.1 INCREASING ADOPTION OF PERSONALIZED MEDICINE 68
    • 5.1.2 ADVANCEMENTS IN GENOMIC TECHNOLOGIES 69
    • 5.1.3 INCREASING CHRONIC AND COMPLEX DISEASES 70
    • 5.1.4 ROLE OF PHARMACOGENETIC TESTING IN DRUG DISCOVERY AND DEVELOPMENT 70
  • 5.2 RESTRAINTS 71
    • 5.2.1 DEPENDENCY ON THE MEDICAL AND GENOMIC EXPERT FOR RESULT INTERPRETATION 71
    • 5.2.2 ETHICAL AND PRIVACY CONCERNS ASSOCIATED WITH PHARMACOGENETIC TESTING 72
  • 5.3 OPPORTUNITIES 72
    • 5.3.1 INTEGRATION WITH ELECTRONIC HEALTH RECORDS (EHRS) 72
    • 5.3.2 ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING INTEGRATION IN HEALTHCARE 73
  • 5.4 CHALLENGES 73
    • 5.4.1 CHALLENGES IN CLINICAL IMPLEMENTATION OF PHARMACOGENETICS 73
    • 5.4.2 COMPLEXITY ASSOCIATED WITH PHARMACOGENETIC TESTING RESULTS 74

6 GLOBAL PHARMACOGENETIC TESTING MARKET, BY TYPE 75

  • 6.1 OVERVIEW 76
  • 6.2 WHOLE GENOME SEQUENCING 79
    • 6.2.1 NEXT GENERATION SEQUENCING (NGS) 79
    • 6.2.2 SANGER SEQUENCING 79
  • 6.3 WHOLE EXOME SEQUENCING 80
    • 6.3.1 NEXT GENERATION SEQUENCING (NGS) 80
    • 6.3.2 SANGER SEQUENCING 80
  • 6.4 ARRAY-BASED TESTS 81
    • 6.4.1 GLASS SLIDE ARRAYS 81
    • 6.4.2 IN-SITU SYNTHESIZED ARRAYS 81
    • 6.4.3 SELF ASSEMBLED ARRAYS 81
  • 6.5 SINGLE GENE TESTS 82
    • 6.5.1 NEXT GENERATION SEQUENCING (NGS) 82
    • 6.5.2 SANGER SEQUENCING 82

7 GLOBAL PHARMACOGENETIC TESTING MARKET, BY GENE TYPE 83

  • 7.1 OVERVIEW 84
  • 7.2 CYP2C19 87
  • 7.3 CYP2D6 87
  • 7.4 CYP2C9 AND VKORC1 88
  • 7.5 CYP1A2 88
  • 7.6 HLA-B*1502 89
  • 7.7 HLA-B*5701 89
  • 7.8 CYP2D 90
  • 7.9 OPRM1 90
  • 7.10 ONCOTYPE DX* AND MAMMAPRINT 91
  • 7.11 DRD3 91
  • 7.12 D4D4 92
  • 7.13 SLC6A4 92
  • 7.14 HTR2A/C 93
  • 7.15 TMPT 93
  • 7.16 OTHERS 94

8 GLOBAL PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE 95

  • 8.1 OVERVIEW 96
  • 8.2 PRESCRIPTION DRUGS 99
  • 8.3 NUTRACEUTICALS 99
  • 8.4 RECREATIONAL DRUGS 100
  • 8.5 HERBAL SUPPLEMENTS 100
  • 8.6 VITAMINS 101
  • 8.7 OVER-THE-COUNTER MEDICATIONS 101

9 GLOBAL PHARMACOGENETIC TESTING MARKET, BY SAMPLE 102

  • 9.1 OVERVIEW 103
  • 9.2 BLOOD 106
  • 9.3 SALIVA 106

10 GLOBAL PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA 107

  • 10.1 OVERVIEW 108
  • 10.2 CARDIOLOGY 111
  • 10.3 GASTROENTEROLOGY 111
  • 10.4 ANESTHESIOLOGY 112
  • 10.5 GENOMICS 112
  • 10.6 ENDOCRINOLOGY 113
  • 10.7 IMMUNOLOGY & HYPERSENSITIVITY 113
  • 10.8 DERMATOLOGY 114
  • 10.9 GYNECOLOGY 114
  • 10.10 ONCOLOGY 115
  • 10.11 NEUROLOGY 115
  • 10.12 OTHERS 116

11 GLOBAL PHARMACOGENETIC TESTING MARKET, BY APPLICATION 117

  • 11.1 OVERVIEW 118
  • 11.2 CLINICAL PRACTICE 121
    • 11.2.1 SIDE EFFECTS 121
    • 11.2.2 DRUG EFFECTIVENESS 121
    • 11.2.3 DOSAGE 122
  • 11.3 DRUG DEVELOPMENT 122
    • 11.3.1 DRUG EFFECTIVENESS 122
    • 11.3.2 DOSAGE 123
    • 11.3.3 SIDE EFFECTS 123
  • 11.4 DRUG REGULATION 123
    • 11.4.1 SIDE EFFECTS 124
    • 11.4.2 DRUG EFFECTIVENESS 124
    • 11.4.3 DOSAGE 124

12 GLOBAL PHARMACOGENETIC TESTING MARKET, BY END USER 125

  • 12.1 OVERVIEW 126
  • 12.2 HEALTHCARE PROVIDERS 129
  • 12.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 129
  • 12.4 RESEARCH CENTRES AND ACADEMIC INSTITUTES 130
  • 12.5 OTHERS 130

13 GLOBAL PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL 131

  • 13.1 OVERVIEW 132
  • 13.2 HOSPITAL PHARMACY 135
  • 13.3 RETAIL PHARMACIES 135
  • 13.4 MAIL-ORDER PHARMACIES 136
  • 13.5 DIRECT-TO-CUSTOMER SERVICES 136

14 GLOBAL PHARMACOGENETIC TESTING MARKET, BY REGION 137

  • 14.1 OVERVIEW 138
  • 14.2 NORTH AMERICA 142
  • 14.3 EUROPE 163
  • 14.4 ASIA-PACIFIC 217
  • 14.5 SOUTH AMERICA 268
  • 14.6 MIDDLE EAST AND AFRICA 290

15 GLOBAL PHARMACOGENETIC TESTING MARKET: COMPANY LANDSCAPE 318

  • 15.1 COMPANY SHARE ANALYSIS: GLOBAL 318
  • 15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 319
  • 15.3 COMPANY SHARE ANALYSIS: EUROPE 320
  • 15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 321

16 SWOT ANALYSIS 322

17 COMPANY PROFILE 323

  • 17.1 THERMO FISHER SCIENTIFIC INC. 323
    • 17.1.1 COMPANY SNAPSHOT 323
    • 17.1.2 REVENUE ANALYSIS 323
    • 17.1.3 COMPANY SHARE ANALYSIS 324
    • 17.1.4 PRODUCT PORTFOLIO 324
    • 17.1.5 RECENT DEVELOPMENTS 324
  • 17.2 ILLUMINA, INC. 326
    • 17.2.1 COMPANY SNAPSHOT 326
    • 17.2.2 REVENUE ANALYSIS 326
    • 17.2.3 COMPANY SHARE ANALYSIS 327
    • 17.2.4 PRODUCT PORTFOLIO 327
    • 17.2.5 RECENT DEVELOPMENT 327
  • 17.3 QIAGEN 329
    • 17.3.1 COMPANY SNAPSHOT 329
    • 17.3.2 REVENUE ANALYSIS 329
    • 17.3.3 COMPANY SHARE ANALYSIS 330
    • 17.3.4 PRODUCT PORTFOLIO 330
    • 17.3.5 RECENT DEVELOPMENT 330
  • 17.4 SONIC HEALTHCARE 331
    • 17.4.1 COMPANY SNAPSHOT 331
    • 17.4.2 REVENUE ANALYSIS 331
    • 17.4.3 COMPANY SHARE ANALYSIS 332
    • 17.4.4 PRODUCT PORTFOLIO 332
    • 17.4.5 RECENT DEVELOPMENT 332
  • 17.5 BGI 333
    • 17.5.1 COMPANY SNAPSHOT 333
    • 17.5.2 COMPANY SHARE ANALYSIS 333
    • 17.5.3 PRODUCT PORTFOLIO 333
    • 17.5.4 RECENT DEVELOPMENT 333
  • 17.6 23ANDME, INC 334
    • 17.6.1 COMPANY SNAPSHOT 334
    • 17.6.2 REVENUE ANALYSIS 334
    • 17.6.3 PRODUCT PORTFOLIO 335
    • 17.6.4 RECENT DEVELOPMENT 335
  • 17.7 DYNAMIC DNA LABORATORIES 336
    • 17.7.1 COMPANY SNAPSHOT 336
    • 17.7.2 PRODUCT PORTFOLIO 336
    • 17.7.3 RECENT DEVELOPMENT 336
  • 17.8 EUROFINS SCIENTIFIC (2022) 337
    • 17.8.1 COMPANY SNAPSHOT 337
    • 17.8.2 REVENUE ANALYSIS 337
    • 17.8.3 PRODUCT PORTFOLIO 338
    • 17.8.4 RECENT DEVELOPMENT 338
  • 17.9 GENEWIX (A SUBSIDIARY OF AZENTA LIFE SCIENCE) 339
    • 17.9.1 COMPANY SNAPSHOT 339
    • 17.9.2 PRODUCT PORTFOLIO 339
    • 17.9.3 RECENT DEVELOPMENT 339
  • 17.10 LUMINEX CORPORATION (A SUBSIDIARY OF DIASORIN) 341
    • 17.10.1 COMPANY SNAPSHOT 341
    • 17.10.2 PRODUCT PORTFOLIO 341
    • 17.10.3 RECENT DEVELOPMENT 341
  • 17.11 MD LABS 342
    • 17.11.1 COMPANY SNAPSHOT 342
    • 17.11.2 PRODUCT PORTFOLIO 342
    • 17.11.3 RECENT DEVELOPMENT 342
  • 17.12 MYRIAD GENETICS, INC. 343
    • 17.12.1 COMPANY SNAPSHOT 343
    • 17.12.2 REVENUE ANALYSIS 343
    • 17.12.3 PRODUCT PORTFOLIO 344
    • 17.12.4 RECENT DEVELOPMENTS 344
  • 17.13 ONEOME 345
    • 17.13.1 COMPANY SNAPSHOT 345
    • 17.13.2 PRODUCT PORTFOLIO 345
    • 17.13.3 RECENT DEVELOPMENT 345
  • 17.14 PACBIO 346
    • 17.14.1 COMPANY SNAPSHOT 346
    • 17.14.2 REVENUE ANALYSIS 346
    • 17.14.3 PRODUCT PORTFOLIO 347
    • 17.14.4 RECENT DEVELOPMENT 347
  • 17.15 PERKINELMER INC. 348
    • 17.15.1 COMPANY SNAPSHOT 348
    • 17.15.2 REVENUE ANALYSIS 348
    • 17.15.3 PRODUCT PORTFOLIO 349
    • 17.15.4 RECENT DEVELOPMENT 349
  • 17.16 PGXT 350
    • 17.16.1 COMPANY SNAPSHOT 350
    • 17.16.2 PRODUCT PORTFOLIO 350
    • 17.16.3 RECENT DEVELOPMENT 350

18 QUESTIONNAIRE 351

19 RELATED REPORTS 356

LIST OF TABLES

  • TABLE 1 GLOBAL PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 78
  • TABLE 2 GLOBAL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 79
  • TABLE 3 GLOBAL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 79
  • TABLE 4 GLOBAL WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 80
  • TABLE 5 GLOBAL WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 80
  • TABLE 6 GLOBAL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 81
  • TABLE 7 GLOBAL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 81
  • TABLE 8 GLOBAL SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 82
  • TABLE 9 GLOBAL SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 82
  • TABLE 10 GLOBAL PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 86
  • TABLE 11 GLOBAL CYP2C19 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 87
  • TABLE 12 GLOBAL CYP2D6 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 87
  • TABLE 13 GLOBAL CYP2C9 AND VKORC1 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 88
  • TABLE 14 GLOBAL CYP1A2 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 88
  • TABLE 15 GLOBAL HLA-B*1502 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 89
  • TABLE 16 GLOBAL HLA-B*5701 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 89
  • TABLE 17 GLOBAL CYP2D IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 90
  • TABLE 18 GLOBAL OPRM1 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 90
  • TABLE 19 GLOBAL ONCOTYPE DX* AND MAMMAPRINT IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 91
  • TABLE 20 GLOBAL DRD3 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 91
  • TABLE 21 GLOBAL D4D4 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 92
  • TABLE 22 GLOBAL SLC6A4 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 92
  • TABLE 23 GLOBAL HTR2A/C IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 93
  • TABLE 24 GLOBAL TMPT IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 93
  • TABLE 25 GLOBAL OTHERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 94
  • TABLE 26 GLOBAL PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 98
  • TABLE 27 GLOBAL PRESCRIPTION DRUGS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 99
  • TABLE 28 GLOBAL NUTRACEUTICALS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 99
  • TABLE 29 GLOBAL RECREATIONAL DRUGS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 100
  • TABLE 30 GLOBAL HERBAL SUPPLEMENTS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 100
  • TABLE 31 GLOBAL VITAMINS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 101
  • TABLE 32 GLOBAL OVER-THE-COUNTER MEDICATIONS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 101
  • TABLE 33 GLOBAL PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 105
  • TABLE 34 GLOBAL BLOOD IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 106
  • TABLE 35 GLOBAL SALIVA IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 106
  • TABLE 36 GLOBAL PHARMACOGENETIC TESTING MARKET, BY THERPAEUTIC AREA, 2021-2030 (USD MILLION) 110
  • TABLE 37 GLOBAL CARDIOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 111
  • TABLE 38 GLOBAL GASTROENTEROLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 111
  • TABLE 39 GLOBAL ANESTHESIOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 112
  • TABLE 40 GLOBAL GENOMICS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 112
  • TABLE 41 GLOBAL ENDOCRINOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 113
  • TABLE 42 GLOBAL IMMUNOLOGY & HYPERSENSITIVITY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 113
  • TABLE 43 GLOBAL DERMATOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 114
  • TABLE 44 GLOBAL GYNECOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 114
  • TABLE 45 GLOBAL ONCOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 115
  • TABLE 46 GLOBAL NEUROLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 115
  • TABLE 47 GLOBAL OTHERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 116
  • TABLE 48 GLOBAL PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 120
  • TABLE 49 GLOBAL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 121
  • TABLE 50 GLOBAL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 121
  • TABLE 51 GLOBAL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 122
  • TABLE 52 GLOBAL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 122
  • TABLE 53 GLOBAL DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 123
  • TABLE 54 GLOBAL DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 123
  • TABLE 55 GLOBAL PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 128
  • TABLE 56 GLOBAL HEALTHCARE PROVIDERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 129
  • TABLE 57 GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 129
  • TABLE 58 GLOBAL RESEARCH CENTRES AND ACADEMIC INSTITUTES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 130
  • TABLE 59 GLOBAL OTHERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 130
  • TABLE 60 GLOBAL PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 134
  • TABLE 61 GLOBAL HOSPITAL PHARMACY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 135
  • TABLE 62 GLOBAL RETAIL PHARMACIES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 135
  • TABLE 63 GLOBAL MAIL-ORDER PHARMACIES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 136
  • TABLE 64 GLOBAL DIRECT-TO-CUSTOMER SERVICES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 136
  • TABLE 65 GLOBAL PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION) 141
  • TABLE 66 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 142
  • TABLE 67 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 142
  • TABLE 68 NORTH AMERICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 142
  • TABLE 69 NORTH AMERICA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 143
  • TABLE 70 NORTH AMERICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 143
  • TABLE 71 NORTH AMERICA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 143
  • TABLE 72 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 144
  • TABLE 73 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 144
  • TABLE 74 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 145
  • TABLE 75 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 145
  • TABLE 76 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 145
  • TABLE 77 NORTH AMERICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 146
  • TABLE 78 NORTH AMERICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 146
  • TABLE 79 NORTH AMERICA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 146
  • TABLE 80 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 146
  • TABLE 81 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 147
  • TABLE 82 U.S. PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 148
  • TABLE 83 U.S. WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 148
  • TABLE 84 U.S. WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 148
  • TABLE 85 U.S. ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 148
  • TABLE 86 U.S. SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 87 U.S. PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 88 U.S. PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 89 U.S. PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 150
  • TABLE 90 U.S. PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 150
  • TABLE 91 U.S. PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 150
  • TABLE 92 U.S. CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 151
  • TABLE 93 U.S. DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 151
  • TABLE 94 U.S. DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 151
  • TABLE 95 U.S. PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 151
  • TABLE 96 U.S. PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 152
  • TABLE 97 CANADA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 153
  • TABLE 98 CANADA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 153
  • TABLE 99 CANADA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 153
  • TABLE 100 CANADA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 153
  • TABLE 101 CANADA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 154
  • TABLE 102 CANADA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 154
  • TABLE 103 CANADA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 154
  • TABLE 104 CANADA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 155
  • TABLE 105 CANADA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 155
  • TABLE 106 CANADA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 155
  • TABLE 107 CANADA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 156
  • TABLE 108 CANADA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 156
  • TABLE 109 CANADA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 156
  • TABLE 110 CANADA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 156
  • TABLE 111 CANADA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 157
  • TABLE 112 MEXICO PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 158
  • TABLE 113 MEXICO WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 158
  • TABLE 114 MEXICO WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 158
  • TABLE 115 MEXICO ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 158
  • TABLE 116 MEXICO SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 159
  • TABLE 117 MEXICO PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 159
  • TABLE 118 MEXICO PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 159
  • TABLE 119 MEXICO PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 160
  • TABLE 120 MEXICO PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 160
  • TABLE 121 MEXICO PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 160
  • TABLE 122 MEXICO CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 161
  • TABLE 123 MEXICO DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 161
  • TABLE 124 MEXICO DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 161
  • TABLE 125 MEXICO PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 161
  • TABLE 126 MEXICO PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 162
  • TABLE 127 EUROPE PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 163
  • TABLE 128 EUROPE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 129 EUROPE WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 130 EUROPE WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 131 EUROPE ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 132 EUROPE SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 133 EUROPE PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 134 EUROPE PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 135 EUROPE PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 165
  • TABLE 136 EUROPE PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 166
  • TABLE 137 EUROPE PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 166
  • TABLE 138 EUROPE CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 166
  • TABLE 139 EUROPE DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 167
  • TABLE 140 EUROPE DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 167
  • TABLE 141 EUROPE PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 167
  • TABLE 142 EUROPE PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 167
  • TABLE 143 GERMANY PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 144 GERMANY WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 145 GERMANY WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 146 GERMANY ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 147 GERMANY SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 148 GERMANY PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 149 GERMANY PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 150 GERMANY PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 170
  • TABLE 151 GERMANY PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 170
  • TABLE 152 GERMANY PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 170
  • TABLE 153 GERMANY CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 171
  • TABLE 154 GERMANY DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 171
  • TABLE 155 GERMANY DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 171
  • TABLE 156 GERMANY PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 171
  • TABLE 157 GERMANY PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 172
  • TABLE 158 FRANCE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 159 FRANCE WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 160 FRANCE WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 161 FRANCE ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 162 FRANCE SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 163 FRANCE PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 164 FRANCE PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 165 FRANCE PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 175
  • TABLE 166 FRANCE PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 175
  • TABLE 167 FRANCE PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 175
  • TABLE 168 FRANCE CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 175
  • TABLE 169 FRANCE DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 176
  • TABLE 170 FRANCE DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 176
  • TABLE 171 FRANCE PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 176
  • TABLE 172 FRANCE PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 176
  • TABLE 173 U.K. PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 174 U.K. WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 175 U.K. WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 176 U.K. ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 177 U.K. SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 178
  • TABLE 178 U.K. PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 178
  • TABLE 179 U.K. PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 178
  • TABLE 180 U.K. PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 179
  • TABLE 181 U.K. PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 179
  • TABLE 182 U.K. PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 179
  • TABLE 183 U.K. CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 180
  • TABLE 184 U.K. DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 180
  • TABLE 185 U.K. DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 180
  • TABLE 186 U.K. PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 180
  • TABLE 187 U.K. PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 181
  • TABLE 188 ITALY PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 182
  • TABLE 189 ITALY WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 182
  • TABLE 190 ITALY WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 182
  • TABLE 191 ITALY ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 182
  • TABLE 192 ITALY SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 183
  • TABLE 193 ITALY PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 183
  • TABLE 194 ITALY PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 183
  • TABLE 195 ITALY PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 184
  • TABLE 196 ITALY PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 184
  • TABLE 197 ITALY PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 184
  • TABLE 198 ITALY CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 184
  • TABLE 199 ITALY DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 185
  • TABLE 200 ITALY DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 185
  • TABLE 201 ITALY PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 185
  • TABLE 202 ITALY PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 185
  • TABLE 203 SPAIN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 186
  • TABLE 204 SPAIN WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 186
  • TABLE 205 SPAIN WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 186
  • TABLE 206 SPAIN ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 186
  • TABLE 207 SPAIN SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 187
  • TABLE 208 SPAIN PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 187
  • TABLE 209 SPAIN PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 187
  • TABLE 210 SPAIN PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 188
  • TABLE 211 SPAIN PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 188
  • TABLE 212 SPAIN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 188
  • TABLE 213 SPAIN CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 189
  • TABLE 214 SPAIN DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 189
  • TABLE 215 SPAIN DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 189
  • TABLE 216 SPAIN PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 189
  • TABLE 217 SPAIN PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 190
  • TABLE 218 RUSSIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 191
  • TABLE 219 RUSSIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 191
  • TABLE 220 RUSSIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 191
  • TABLE 221 RUSSIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 191
  • TABLE 222 RUSSIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 192
  • TABLE 223 RUSSIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 192
  • TABLE 224 RUSSIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 192
  • TABLE 225 RUSSIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 193
  • TABLE 226 RUSSIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 193
  • TABLE 227 RUSSIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 193
  • TABLE 228 RUSSIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 194
  • TABLE 229 RUSSIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 194
  • TABLE 230 RUSSIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 194
  • TABLE 231 RUSSIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 194
  • TABLE 232 RUSSIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 195
  • TABLE 233 TURKEY PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 196
  • TABLE 234 TURKEY WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 196
  • TABLE 235 TURKEY WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 196
  • TABLE 236 TURKEY ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 196
  • TABLE 237 TURKEY SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 197
  • TABLE 238 TURKEY PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 197
  • TABLE 239 TURKEY PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 197
  • TABLE 240 TURKEY PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 198
  • TABLE 241 TURKEY PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 198
  • TABLE 242 TURKEY PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 198
  • TABLE 243 TURKEY CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 199
  • TABLE 244 TURKEY DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 199
  • TABLE 245 TURKEY DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 199
  • TABLE 246 TURKEY PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 199
  • TABLE 247 TURKEY PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 200
  • TABLE 248 BELGIUM PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 201
  • TABLE 249 BELGIUM WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 201
  • TABLE 250 BELGIUM WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 201
  • TABLE 251 BELGIUM ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 201
  • TABLE 252 BELGIUM SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 202
  • TABLE 253 BELGIUM PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 202
  • TABLE 254 BELGIUM PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 202
  • TABLE 255 BELGIUM PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 203
  • TABLE 256 BELGIUM PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 203
  • TABLE 257 BELGIUM PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 203
  • TABLE 258 BELGIUM CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 204
  • TABLE 259 BELGIUM DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 204
  • TABLE 260 BELGIUM DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 204
  • TABLE 261 BELGIUM PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 204
  • TABLE 262 BELGIUM PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 205
  • TABLE 263 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 206
  • TABLE 264 NETHERLANDS WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 206
  • TABLE 265 NETHERLANDS WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 206
  • TABLE 266 NETHERLANDS ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 206
  • TABLE 267 NETHERLANDS SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 207
  • TABLE 268 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 207
  • TABLE 269 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 208
  • TABLE 270 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 208
  • TABLE 271 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 208
  • TABLE 272 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 209
  • TABLE 273 NETHERLANDS CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 209
  • TABLE 274 NETHERLANDS DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 209
  • TABLE 275 NETHERLANDS DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 209
  • TABLE 276 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 210
  • TABLE 277 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 210
  • TABLE 278 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 210
  • TABLE 279 SWITZERLAND WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 210
  • TABLE 280 SWITZERLAND WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 211
  • TABLE 281 SWITZERLAND ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 211
  • TABLE 282 SWITZERLAND SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 211
  • TABLE 283 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 212
  • TABLE 284 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 212
  • TABLE 285 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 213
  • TABLE 286 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 213
  • TABLE 287 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 213
  • TABLE 288 SWITZERLAND CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 214
  • TABLE 289 SWITZERLAND DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 214
  • TABLE 290 SWITZERLAND DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 214
  • TABLE 291 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 214
  • TABLE 292 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 215
  • TABLE 293 REST OF EUROPE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 216
  • TABLE 294 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 217
  • TABLE 295 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 217
  • TABLE 296 ASIA-PACIFIC WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 218
  • TABLE 297 ASIA-PACIFIC WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 218
  • TABLE 298 ASIA-PACIFIC ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 218
  • TABLE 299 ASIA-PACIFIC SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 218
  • TABLE 300 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 219
  • TABLE 301 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 219
  • TABLE 302 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 220
  • TABLE 303 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 220
  • TABLE 304 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 220
  • TABLE 305 ASIA-PACIFIC CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 221
  • TABLE 306 ASIA-PACIFIC DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 221
  • TABLE 307 ASIA-PACIFIC DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 221
  • TABLE 308 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 221
  • TABLE 309 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 222
  • TABLE 310 JAPAN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 223
  • TABLE 311 JAPAN WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 223
  • TABLE 312 JAPAN WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 223
  • TABLE 313 JAPAN ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 223
  • TABLE 314 JAPAN SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 224
  • TABLE 315 JAPAN PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 224
  • TABLE 316 JAPAN PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 224
  • TABLE 317 JAPAN PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 225
  • TABLE 318 JAPAN PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 225
  • TABLE 319 JAPAN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 225
  • TABLE 320 JAPAN CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 226
  • TABLE 321 JAPAN DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 226
  • TABLE 322 JAPAN DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 226
  • TABLE 323 JAPAN PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 226
  • TABLE 324 JAPAN PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 227
  • TABLE 325 CHINA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 228
  • TABLE 326 CHINA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 228
  • TABLE 327 CHINA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 228
  • TABLE 328 CHINA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 228
  • TABLE 329 CHINA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 229
  • TABLE 330 CHINA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 229
  • TABLE 331 CHINA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 229
  • TABLE 332 CHINA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 230
  • TABLE 333 CHINA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 230
  • TABLE 334 CHINA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 230
  • TABLE 335 CHINA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 230
  • TABLE 336 CHINA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 231
  • TABLE 337 CHINA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 231
  • TABLE 338 CHINA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 231
  • TABLE 339 CHINA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 231
  • TABLE 340 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 232
  • TABLE 341 SOUTH KOREA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 232
  • TABLE 342 SOUTH KOREA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 232
  • TABLE 343 SOUTH KOREA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 232
  • TABLE 344 SOUTH KOREA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 233
  • TABLE 345 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 233
  • TABLE 346 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 233
  • TABLE 347 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 234
  • TABLE 348 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 234
  • TABLE 349 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 234
  • TABLE 350 SOUTH KOREA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 235
  • TABLE 351 SOUTH KOREA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 235
  • TABLE 352 SOUTH KOREA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 235
  • TABLE 353 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 235
  • TABLE 354 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 236
  • TABLE 355 INDIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 237
  • TABLE 356 INDIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 237
  • TABLE 357 INDIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 237
  • TABLE 358 INDIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 237
  • TABLE 359 INDIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 238
  • TABLE 360 INDIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 238
  • TABLE 361 INDIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 238
  • TABLE 362 INDIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 239
  • TABLE 363 INDIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 239
  • TABLE 364 INDIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 239
  • TABLE 365 INDIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 239
  • TABLE 366 INDIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 240
  • TABLE 367 INDIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 240
  • TABLE 368 INDIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 240
  • TABLE 369 INDIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 240
  • TABLE 370 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 241
  • TABLE 371 AUSTRALIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 241
  • TABLE 372 AUSTRALIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 241
  • TABLE 373 AUSTRALIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 241
  • TABLE 374 AUSTRALIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 242
  • TABLE 375 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 242
  • TABLE 376 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 242
  • TABLE 377 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 243
  • TABLE 378 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 243
  • TABLE 379 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 243
  • TABLE 380 AUSTRALIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 243
  • TABLE 381 AUSTRALIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 244
  • TABLE 382 AUSTRALIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 244
  • TABLE 383 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 244
  • TABLE 384 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 244
  • TABLE 385 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 245
  • TABLE 386 SINGAPORE WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 245
  • TABLE 387 SINGAPORE WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 245
  • TABLE 388 SINGAPORE ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 245
  • TABLE 389 SINGAPORE SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 246
  • TABLE 390 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 246
  • TABLE 391 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 246
  • TABLE 392 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 247
  • TABLE 393 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 247
  • TABLE 394 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 247
  • TABLE 395 SINGAPORE CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 247
  • TABLE 396 SINGAPORE DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 248
  • TABLE 397 SINGAPORE DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 248
  • TABLE 398 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 248
  • TABLE 399 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 248
  • TABLE 400 THAILAND PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 249
  • TABLE 401 THAILAND WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 249
  • TABLE 402 THAILAND WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 249
  • TABLE 403 THAILAND ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 249
  • TABLE 404 THAILAND SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION) 250
  • TABLE 405 THAILAND PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION) 250
  • TABLE 406 THAILAND PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 250
  • TABLE 407 THAILAND PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION) 251
  • TABLE 408 THAILAND PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION) 251
  • TABLE 409 THAILAND PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 251
  • TABLE 410 THAILAND CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 251
  • TABLE 411 THAILAND DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 252
  • TABLE 412 THAILAND DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 252
  • TABLE 413 THAILAND PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION) 252

LIST OF FIGURES

  • FIGURE 1 GLOBAL PHARMACOGENETIC TESTING MARKET: SEGMENTATION 46
  • FIGURE 2 GLOBAL PHARMACOGENETIC TESTING MARKET: DATA TRIANGULATION 49
  • FIGURE 3 GLOBAL PHARMACOGENETIC TESTING MARKET: DROC ANALYSIS 50
  • FIGURE 4 GLOBAL PHARMACOGENETIC TESTING MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 51
  • FIGURE 5 GLOBAL PHARMACOGENETIC TESTING MARKET: COMPANY RESEARCH ANALYSIS 51
  • FIGURE 6 GLOBAL PHARMACOGENETIC TESTING MARKET: INTERVIEW DEMOGRAPHICS 52
  • FIGURE 7 GLOBAL PHARMACOGENETIC TESTING MARKET: DBMR MARKET POSITION GRID 53
  • FIGURE 8 GLOBAL PHARMACOGENETIC TESTING MARKET: MARKET END USER COVERAGE GRID 56
  • FIGURE 9 GLOBAL PHARMACOGENETIC TESTING MARKET: SEGMENTATION 60
  • FIGURE 10 INCREASING ADOPTION OF PERSONALIZED MEDICINE IS DRIVING THE GROWTH OF THE GLOBAL PHARMACOGENETIC TESTING MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 61
  • FIGURE 11 WHOLE GENOME SEQUENCING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PHARMACOGENETIC TESTING MARKET IN 2023 & 2030 61
  • FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL PHARMACOGENETIC TESTING MARKET 66
  • FIGURE 13 GLOBAL PHARMACOGENETIC TESTING MARKET: BY TYPE, 2022 75
  • FIGURE 14 GLOBAL PHARMACOGENETIC TESTING MARKET: BY TYPE, 2023-2030 (USD MILLION) 76
  • FIGURE 15 GLOBAL PHARMACOGENETIC TESTING MARKET: BY TYPE, CAGR (2023-2030) 76
  • FIGURE 16 GLOBAL PHARMACOGENETIC TESTING MARKET: BY TYPE, LIFELINE CURVE 77
  • FIGURE 17 GLOBAL PHARMACOGENETIC TESTING MARKET: BY GENE TYPE, 2022 83
  • FIGURE 18 GLOBAL PHARMACOGENETIC TESTING MARKET: BY GENE TYPE, 2023-2030 (USD MILLION) 84
  • FIGURE 19 GLOBAL PHARMACOGENETIC TESTING MARKET: BY GENE TYPE, CAGR (2023-2030) 84
  • FIGURE 20 GLOBAL PHARMACOGENETIC TESTING MARKET: BY GENE TYPE, LIFELINE CURVE 85
  • FIGURE 21 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DRUG TYPE, 2022 95
  • FIGURE 22 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION) 96
  • FIGURE 23 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DRUG TYPE, CAGR (2023-2030) 96
  • FIGURE 24 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DRUG TYPE, LIFELINE CURVE 97
  • FIGURE 25 GLOBAL PHARMACOGENETIC TESTING MARKET: BY SAMPLE, 2022 102
  • FIGURE 26 GLOBAL PHARMACOGENETIC TESTING MARKET: BY SAMPLE, 2023-2030 (USD MILLION) 103
  • FIGURE 27 GLOBAL PHARMACOGENETIC TESTING MARKET: BY SAMPLE, CAGR (2023-2030) 103
  • FIGURE 28 GLOBAL PHARMACOGENETIC TESTING MARKET: BY SAMPLE, LIFELINE CURVE 104
  • FIGURE 29 GLOBAL PHARMACOGENETIC TESTING MARKET: BY THERAPEUTIC AREA, 2022 107
  • FIGURE 30 GLOBAL PHARMACOGENETIC TESTING MARKET: BY THERAPEUTIC AREA, 2023-2030 (USD MILLION) 108
  • FIGURE 31 GLOBAL PHARMACOGENETIC TESTING MARKET: BY THERAPEUTIC AREA, CAGR (2023-2030) 108
  • FIGURE 32 GLOBAL PHARMACOGENETIC TESTING MARKET: BY THERAPEUTIC AREA, LIFELINE CURVE 109
  • FIGURE 33 GLOBAL PHARMACOGENETIC TESTING MARKET: BY APPLICATION, 2022 117
  • FIGURE 34 GLOBAL PHARMACOGENETIC TESTING MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 118
  • FIGURE 35 GLOBAL PHARMACOGENETIC TESTING MARKET: BY APPLICATION, CAGR (2023-2030) 118
  • FIGURE 36 GLOBAL PHARMACOGENETIC TESTING MARKET: BY APPLICATION, LIFELINE CURVE 119
  • FIGURE 37 GLOBAL PHARMACOGENETIC TESTING MARKET: BY END USER, 2022 125
  • FIGURE 38 GLOBAL PHARMACOGENETIC TESTING MARKET: BY END USER, 2023-2030 (USD MILLION) 126
  • FIGURE 39 GLOBAL PHARMACOGENETIC TESTING MARKET: BY END USER, CAGR (2023-2030) 126
  • FIGURE 40 GLOBAL PHARMACOGENETIC TESTING MARKET: BY END USER, LIFELINE CURVE 127
  • FIGURE 41 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DISTRIBUTION CHANNEL, 2022 131
  • FIGURE 42 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 132
  • FIGURE 43 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 132
  • FIGURE 44 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 133
  • FIGURE 45 GLOBAL PHARMACOGENETIC TESTING MARKET: SNAPSHOT (2022) 138
  • FIGURE 46 GLOBAL PHARMACOGENETIC TESTING MARKET: COMPANY SHARE 2022 (%) 317
  • FIGURE 47 NORTH AMERICA PHARMACOGENETIC TESTING MARKET: COMPANY SHARE 2022 (%) 318
  • FIGURE 48 EUROPE PHARMACOGENETIC TESTING MARKET: COMPANY SHARE 2022 (%) 319
  • FIGURE 49 AISA-PACIFIC PHARMACOGENETIC TESTING MARKET: COMPANY SHARE 2022 (%) 320